Company news

Larimar Therapeutics, Inc. news in 2025

Larimar Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

November 5, 2025

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

September 29, 2025

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

September 28, 2025

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

August 14, 2025

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

July 31, 2025

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

July 29, 2025

Larimar Therapeutics Announces Proposed Underwritten Public Offering

July 29, 2025

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

July 8, 2025

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program

June 23, 2025

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

June 20, 2025

Larimar Therapeutics Reports First Quarter 2025 Financial Results

April 30, 2025

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

March 24, 2025

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

March 3, 2025

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

January 22, 2025

Decks in 2025